Bolt Biotherapeutics, Inc. BOLT 深 沪
已收盘 02-06 16:00:00 美东时间
5.77
+0.370
+6.85%
华盛通- 最 高6.14
- 今 开5.94
- 成交量 3.08万股
- 最 低 5.405
- 昨 收 5.40
- 总市值 1107.52万
- 52周最高 10.40
- 市盈率 静 --
- 换手率 1.60%
- 52周最低 4.41
- 委 比 48.70%
- 总股本 191.94万
- 历史最高 861.40
- 量 比 0.78
- 振 幅 13.61%
- 历史最低 5.20
- 每 手 1
- 风险率 1.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ADVISORY-Alert wrongly tagged to Bolt Biotherapeutics Inc withdrawn
ADVISORY-Alert wrongly tagged to Bolt Biotherapeutics Inc withdrawn An alert on privately-held company Bolt providing checkout, identity and payments services was wrongly tagged to Bolt Biotherapeutics BOLT.O , an unrelated entity, and has been withdrawn. There will be no substitute. STORY_NUMBER:nT
01-22 23:28
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Adlai Nortye (NASDAQ:ANL) stock moved upwards by 44.5% to $2.37 during...
2025-12-29 20:05
Bolt Biotherapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.
Bolt Biotherapeutics shares are trading higher after the company reported bette...
2025-11-13 22:18
Bolt Metals Corrects Private Placement Amount in Recent Announcement
An announcement from Bolt Metals ( ($TSE:BOLT) ) is now available. Bolt Metals ...
2025-10-24 01:39
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
2025-10-21 18:13
HC Wainwright & Co. Assumes Bolt Biotherapeutics at Buy, Announces Price Target of $7
HC Wainwright & Co. analyst Robert Burns assumes Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy rating and announces Price Target of $7.
2025-10-20 18:44
Bolt Biotherapeutics Announces Major Restructuring Plan
An announcement from Bolt Biotherapeutics ( ($BOLT) ) is now available. On Octo...
2025-10-03 04:37
Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket
Shares of Concorde International Group Ltd. (NASDAQ:CIGL) rose sharply in pre-m...
2025-10-02 17:48
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
Bolt Biotherapeutics announced that initial clinical data for its Phase 1 dose escalation study of BDC-4182, targeting claudin 18.2, is now expected in the third quarter of 2026. The company is modifying the trial protocol to allow for step-up dosing, informed by strong preclinical data. Additionally, Bolt has implemented a 50% workforce reduction to extend its cash runway into 2027, aiming to conserve capital and maintain shareholder value.
2025-10-01 20:05
Bolt Metals Corp. Announces CAD$600,000 Private Placement
Bolt Metals ( ($TSE:BOLT) ) has shared an update. Bolt Metals Corp. has announc...
2025-09-30 08:38
